Advancing understanding of the physiology of the cardiovascular system and the mechanisms of disease progression has been central to our research since the inception of the William Harvey Research Institute by Sir John Vane in 1986. Our Vascular pharmacology programmes investigate mechanisms of vascular homeostasis in inflammation (Thiemermann, Solito, Corder, Hinds, Pearse), acute & chronic renal disease, platelet biology (Warner) and generate candidate molecules (Ahluwalia, Hobbs, Caulfield) and regenerative cellular therapies (Suzuki, Xiao, Yashiro, Shintani and Mathur) for vascular disease prevention and Treatment. A more recent venture operating within this theme is a cross-WHRI initiative led by Dunkel with Tinker which is the development of a new Human Laboratory of inducible pluripotent stem cells as models of human disease for both functional and pharmacological testing of endocrine and CV disorders. With respect to the latter we have a major interest in determining the underlying mechanisms particularly focussing on ion channel candidates in cardiac rhythm disturbances (Tinker).
A major research theme at the WHRI within the context of cardiovascular disease focuses on understanding the involvement of the innate and adaptive immune responses. These processes are known to play a key role in the pathogenesis and perpetuation of a number of cardiovascular diseases, including heart transplant rejection, atherosclerosis and hypertension. Under the leadership of Professor Federica Marelli-Berg with Mauro and Longhi we are investigating the immunological cellular and molecular mediators of these conditions.